Study of Safety And Efficacy Of ReFacto AF In Previously Untreated Hemophilia A Patients In The Usual Care Setting
Launched by PFIZER · Jul 30, 2009
Trial Information
Current as of June 03, 2025
Completed
Keywords
ClinConnect Summary
Regulatory Commitment
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Male subjects \<6 years of age with severe hemophilia A (FVIII:C \<1%) based on clinical records, including newborns.
- • No prior exposure to factor products or any blood products.
- Exclusion Criteria:
- • Presence of any bleeding disorder in addition to hemophilia A.
- • Treatment with any investigational agent or device within the past 30 days.
- • Any condition(s) that compromises the ability to collect study-related observations, or that poses a contraindication to study participation (these conditions include, but are not limited to, inadequate medical history to assure study eligibility; and expectation of poor adherence to study requirements).
About Pfizer
Pfizer Inc. is a global leader in biopharmaceutical innovation, dedicated to discovering, developing, and delivering advanced therapies that enhance patient outcomes across a wide range of medical conditions. With a rich history of scientific research and a commitment to quality, Pfizer focuses on areas such as oncology, immunology, cardiology, and rare diseases. The company leverages cutting-edge technology and collaborates with healthcare professionals, regulatory bodies, and academic institutions to conduct rigorous clinical trials that ensure the safety and efficacy of its products. Pfizer's mission is to bring breakthroughs that change patients' lives, exemplifying its commitment to health and wellness worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Madrid, , Spain
Valencia, , Spain
Groningen, , Netherlands
Nantes, , France
Bremen, , Germany
Hannover, Niedersachsen, Germany
Firenze, , Italy
Bornova, Izmir, Turkey
Adana, , Turkey
Istanbul, , Turkey
Lviv, , Ukraine
Patients applied
Trial Officials
Pfizer CT.gov Call Center
Study Director
Pfizer
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials